drugset / Trial / NCT04896320
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2023-06-19
- Completion
- 2023-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucatinib | Small molecule | 300 mg | Oral |